# A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)

> **NCT01340053** · PHASE2 · COMPLETED · sponsor: **Ardelyx** · enrollment: 186 (actual)

## Conditions studied

- Constipation Predominant Irritable Bowel Syndrome

## Interventions

- **DRUG:** RDX5791

## Key facts

- **NCT ID:** NCT01340053
- **Lead sponsor:** Ardelyx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2011-12
- **Final completion:** 2012-02
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2019-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01340053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01340053, "A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01340053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*